Citation Information :
Das D, Sharma BS, Mitra A, Mahajon B. Clinical Efficacy and Safety of Brihat Gangadhara Churna in the Management of Irritable Bowel Syndrome: A Prospective Open-label Study. J Res Ayurvedic Sci 2019; 3 (3):92-99.
Background: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and has been confounding physicians with its multifaceted etiology and varying presentations since long. Ayurveda associates this condition with the structural or functional impairment of the organ Grahani, secondary to impairment of Agni and imbalance of Dosha in the gastrointestinal tract. Brihat Gangadhara Churna is a drug of repute preferred by physicians of Ayurveda for managing the morbidities of Agni and Vata in Koshtha.
Objectives: To evaluate the clinical safety and efficacy of Brihat Gangadhara Churna in the management of IBS.
Materials and methods: A prospective open-label interventional single-arm study was carried out in peripheral Institute of Central Council for Research in Ayurvedic Sciences (CCRAS). A total of 90 subjects fulfilling the inclusion and exclusion criteria were recruited in the trial, of which 85 subjects completed the trial. Brihat Gangadhara Churna, in the dose of 3 g twice a day orally after food with honey as Anupana for 12 weeks was given as intervention. Follow-up was done for a period of another 2 weeks without any medication. Assessment parameters including IBS severity score, World Health Organization-Quality of Life Brief Version of the Instrument (WHO-QOL BREF) along with Ayurvedic assessment parameters were assessed every 14 days during 12 weeks of intervention as well as at the end of follow-up period, i.e., 14th week. Paired sample t test was used to compare mean change in the parameters from baseline to 84th day. A value of <0.05 was considered significant.
Results: At the end of treatment period of 84 days as compared with baseline data, significant (p < 0.001) improvement in IBS severity score and all the four domains of WHO-QOL BREF was observed.
Conclusion:Brihat Gangadhara Churna in the above-mentioned dose was found effective and absolutely safe in the management of IBS.
Foxx-Orenstein A. IBS-review and what's new. Med Gen Med 2006;8(3):20.
Karantanos T, Markoutsaki T, Gazouli M, et al. Current insights into the pathophysiology of irritable bowel syndrome. Gut Pathog 2010;2(1):3. DOI: 10.1186/1757-4749-2-3.
Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22(10):935–942. DOI: 10.1111/j.1365-2036.2005.02671.x.
Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanism and practical management. Gut 2007;56(12):1770–1798. DOI: 10.1136/gut.2007.119446.
Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2008;27(1):22–28.
Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977;196(4286):129–136. DOI: 10.1126/science.847460.
Drossman DA. Gastrointestinal illness and the biopsychosocial model. J Clin Gastroenterol 1996;22(4):252–254. DOI: 10.1097/00004836-199606000-00002.